| Prev Close | 231.26 |
| Day Low/High | 226.96 / 231.42 |
| 52 Wk Low/High | 216.12 / 388.67 |
| Avg Volume | 2.55M |
Latest News
Ups and Downs on the Way
Expect a bout of volatility next week as we straddle between oversold and overbought.
Rally? What Rally?
Tuesday's rise disappointed, but any downside from here should bring on negative sentiment while we’re oversold, which should give us a real rally.
Real Money Post-Industrial Average Leaves Major Indices in the Dust
RMPIA outperformed once gain during April.
Breakthrough Tuesday
New highs grow on the New York Stock Exchange and the Investor Intelligence bulls finally tops 55%.
Feels Like Deja Tuesday
Friday felt a lot like Tuesday -- in that it didn’t change any of the big indicators -- but we should still pay close attention to the Citigroup Panic/Euphoria Index, which is now kissing the underside of Euphoria.
Cramer's Takeaways for Ford, Chevron, Alibaba, Biogen, Visa
What are the main takeaways from Chevron, Ford and others? Cramer explains.
Jim Cramer Responds to Elon Musk, Talks Intel, Chevron, Ford and More
Need a road map to close out this week on Wall Street? Jim Cramer breaks down everything investors need to know about the markets from Chevron to Intel.
Jim Cramer Responds to Elon Musk, Talks Intel, Chevron, Ford and More
Need a road map to close out this week on Wall Street? Jim Cramer breaks down everything investors need to know about the markets from Chevron to Intel.
Investing's Not a Game: Cramer's 'Mad Money' Recap (Thursday 4/25/19)
Jim Cramer says it's the start CNBC's annual Stock Draft Contest, but he cautions Mad Money viewers that although investing can be fun, it requires discipline and doing your homework.
Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft
Analyzing this year's stock draft contest and individual stock-picking vs. indexing.
Biogen Shares Fall After Drugmaker Meets Earnings Estimates
The stock dips after the drugmaker beats quarterly revenue estimates and earnings meet forecasts.
Netflix Taking a Knife to a Gunfight with Disney, Apple, Plus Bitcoin
Bitcoin, the most famous of all crypto-currencies, has enjoyed something of a rebound of late.
Boeing, Snap, Texas Instruments, Microsoft and Facebook - 5 Things You Must Know
U.S. stock futures are mixed, following record highs on Wall Street, as investors pause ahead of another wave of corporate earnings reports; Snap's first-quarter revenue beat expectations and the social media company reports a narrower-than-expected loss; Texas Instruments cautions that a much-anticipated rebound in global semiconductor demand could be delayed into the early half of next year.
Patients Living With Spinal Muscular Atrophy (SMA) In The Province Of Saskatchewan Gain Access To SPINRAZA™ (nusinersen)
The Government of the province of Saskatchewan has informed treating physicians that it will grant access to SPINRAZA™ to patients living with Spinal Muscular Atrophy (SMA) Saskatchewan is the second province after the province of Quebec to grant broad...
10 Speculative Stock Plays in the Biotech Sector
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Are These Stocks the Best of the Best?
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
Stepping Carefully Into the Second Quarter
The potential for so-so earnings results among the S&P 500 and an initial lackluster response to IPOs could cause investors to pause a bit after a strong first three months of 2019.
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACB, ECHO, EPAY, HMTV, MYOK, NVDA, PFIE, TGE, TU Downgrades: BIIB, HBB, KEQU, MGYR, OBCI, OLP, PTMN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
How I Use Options to Mitigate Risk and Create Income
Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.
Future Brightens for 2 Small Biotech Stocks
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
Dow Ends Slightly Higher Despite Slowing Global Growth Worries
The Dow Jones Industrial Average trades lower over fears on Wall Street of slowing global growth.
Biogen Announces $5 Billion Buyback Just Days After Stock Plunge
Biogen's board approves a share buyback program days after revealing a phase III trial of a promising Alzheimer's drug is being shelved.
Dow Ends Solidly Higher as Investors Shrug Off Fed Warning of Slowing Growth
Stocks are higher Thursday with the Dow up on strength in Apple.
Should You Buy the Biogen Dip?
Biogen shares are plunging almost 30% Thursday. Is this a screaming buy opportunity or a giant red flag?
Biogen May Shed $18 Billion in Value After Scrapping Alzheimer's Drug Trial
Biogen shares plunge Thursday, wiping nearly $20 billion in value from the biotech group, after it dropped a late-stage trial for a key Alzheimer's disease drug.
Powell and Company Can Influence the Macro, but Not the Micro
All the money in the world cannot change the fact that rising stock prices and falling earnings make the market more expensive.
